Trial Profile
A Prospective, Non-Randomized Cohort Study Assessing Changes in Systemic Vascular Endothelial Growth Factor Levels after Intravitreal Injection of Aflibercept in Infants with Retinopathy of Prematurity
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab
- Indications Retinopathy of prematurity
- Focus Pharmacodynamics
- 18 May 2018 New trial record